Pause or pop? study tests if stopping GLP-1 drugs before endoscopy reduces stomach risks

NCT ID NCT06533527

Completed Knowledge-focused Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 4 trial at the Cleveland Clinic enrolled 69 adults with type 2 diabetes or obesity who take GLP-1 medications. Participants were randomly assigned to either continue or pause their GLP-1 drug before an upper endoscopy. The goal was to see if holding the medication reduces the amount of food or liquid left in the stomach, which can interfere with the procedure or cause dangerous aspiration. The study did not test a new treatment but aimed to improve safety guidelines for common procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 medications (e.g., tirzepatide, semaglutide, liraglutide, dulaglutide)
What this could lead to: If successful, this could lead to updated guidelines on whether to pause GLP-1 drugs before endoscopy to reduce stomach contents and aspiration risk.
What could go wrong: This is a small, single-center trial with only 69 participants. Results may not apply to all patients or settings, and the study does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroparesis Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2 GASTROPARESIS OBESITY

Contacts and locations

Locations

Cleveland Clinic

Weston, Florida, 33331, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.